This week kicked off with the U.S. Court of Appeals for the Third Circuit agreeing with drug makers that HHS cannot require AstraZeneca, Sanofi and Novo Nordisk to offer 340B discounts on drugs dispensed through an unlimited number of contract pharmacies -- the latest ruling in just one of many 340B cases working its way through the courts. Meanwhile, CMS is collecting information to help it prepare for Medicare’s first round of drug price negotiations, a bipartisan duo of senators...